BRIEF-EMA Says 'Mix-And-Match' Approach Can Be Used For Both Initial Courses And Boosters

European Medicines Agency: * EMA: EMA AND ECDC RECOMMENDATIONS ON HETEROLOGOUS VACCINATION COURSES AGAINST COVID-19: 07/12/2021

* EMA SAYS THE 'MIX-AND-MATCH APPROACH CAN BE USED FOR BOTH INITIAL COURSES AND BOOSTERS * EMA SAYS CONTINUE TO URGE ALL EU CITIZENS TO GET FULLY VACCINATED AND TO ADHERE TO RECENT RECOMMENDATIONS ON BOOSTER VACCINATION.

* EMA SAYS THE USE OF A VIRAL VECTOR VACCINE AS THE SECOND DOSE IN PRIMARY VACCINATION SCHEMES, OR THE USE OF TWO DIFFERENT MRNA VACCINES, IS LESS WELL STUDIED. * EMA SAYS EVIDENCE ON HETEROLOGOUS VACCINATION SUGGESTS COMBINATION OF VIRAL VECTOR VACCINES AND MRNA VACCINES PRODUCES GOOD LEVELS OF ANTIBODIES AGAINST COVID-19 VIRUS

* EMA SAYS USE OF HETEROLOGOUS SCHEDULES MAY OFFER FLEXIBILITY IN TERMS OF VACCINATION OPTIONS, PARTICULARLY TO REDUCE IMPACT ON VACCINE ROLLOUT * EMA SAYS REVIEW DID NOT LOOK AT OTHER VACCINES NOT YET LICENSED IN EU

* EMA: EVIDENCE ON HETEROLOGOUS VACCINATION SUGGESTS COMBINATION OF VIRAL VECTOR VACCINES, MRNA VACCINES PRODUCES HIGHER T-CELL RESPONSE VERSUS SAME VACCINE WHETHER IN PRIMARY OR BOOSTER REGIMEN * EMA SAYS OVERALL DATA PRESENTED SUPPORT USE OF MIXED VECTOR/MRNA SCHEDULES.

* EMA SAYS RESEARCH INTO HETEROLOGOUS COMBINATIONS WILL BE TAKEN INTO ACCOUNT IN THE FUTURE IF THESE ARE LICENSED AND MORE EVIDENCE BECOMES AVAILABLE * EMA SAYS HETEROLOGOUS REGIMENS WERE GENERALLY WELL TOLERATED

* EMA SAYS MARKETING AUTHORISATION HOLDERS ARE ALSO BEING ENCOURAGED TO SUBMIT VARIATIONS TO ADD DETAILS ABOUT SUCH USE TO THE PRODUCT INFORMATION.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)